Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 99 | 2024 | 21206 | 4.970 |
Why?
|
Peripheral Nervous System Diseases | 12 | 2024 | 716 | 3.610 |
Why?
|
Exercise | 49 | 2025 | 5955 | 3.550 |
Why?
|
Exercise Therapy | 23 | 2025 | 939 | 3.050 |
Why?
|
Survivors | 29 | 2022 | 2381 | 2.690 |
Why?
|
Acupuncture Therapy | 5 | 2024 | 486 | 2.380 |
Why?
|
Neoplasms | 50 | 2025 | 22365 | 2.330 |
Why?
|
Music Therapy | 4 | 2023 | 111 | 2.300 |
Why?
|
Aromatase Inhibitors | 13 | 2019 | 519 | 2.120 |
Why?
|
Yoga | 3 | 2022 | 280 | 1.760 |
Why?
|
Obesity | 33 | 2023 | 13091 | 1.720 |
Why?
|
Quality of Life | 41 | 2025 | 13489 | 1.540 |
Why?
|
Life Style | 21 | 2024 | 3932 | 1.450 |
Why?
|
Physical Fitness | 8 | 2019 | 744 | 1.330 |
Why?
|
Antineoplastic Agents | 20 | 2025 | 13658 | 1.180 |
Why?
|
Metformin | 14 | 2024 | 909 | 1.160 |
Why?
|
Weight Loss | 11 | 2022 | 2721 | 0.980 |
Why?
|
Mind-Body Therapies | 3 | 2023 | 294 | 0.980 |
Why?
|
Fatigue | 13 | 2025 | 1557 | 0.970 |
Why?
|
Health Behavior | 7 | 2024 | 2650 | 0.940 |
Why?
|
Hot Flashes | 2 | 2024 | 330 | 0.920 |
Why?
|
Body Weight | 10 | 2022 | 4628 | 0.910 |
Why?
|
Acupressure | 1 | 2023 | 16 | 0.870 |
Why?
|
Body Mass Index | 15 | 2023 | 13053 | 0.860 |
Why?
|
Receptors, Estrogen | 8 | 2024 | 2253 | 0.820 |
Why?
|
Acupuncture, Ear | 1 | 2022 | 13 | 0.800 |
Why?
|
Medical Oncology | 10 | 2022 | 2341 | 0.770 |
Why?
|
Female | 126 | 2024 | 397113 | 0.730 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2023 | 11873 | 0.720 |
Why?
|
Humans | 177 | 2025 | 767991 | 0.690 |
Why?
|
Mobility Limitation | 1 | 2024 | 409 | 0.680 |
Why?
|
Receptor, erbB-2 | 8 | 2022 | 2601 | 0.650 |
Why?
|
Diet | 12 | 2024 | 8087 | 0.630 |
Why?
|
Anxiety | 8 | 2023 | 4672 | 0.590 |
Why?
|
Telemedicine | 4 | 2023 | 3109 | 0.580 |
Why?
|
Neoplasm Recurrence, Local | 14 | 2022 | 9412 | 0.550 |
Why?
|
Nutrition Surveys | 1 | 2024 | 1738 | 0.540 |
Why?
|
Physical Endurance | 2 | 2009 | 369 | 0.510 |
Why?
|
Paclitaxel | 5 | 2024 | 1728 | 0.510 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2024 | 1751 | 0.500 |
Why?
|
Tertiary Prevention | 1 | 2015 | 8 | 0.490 |
Why?
|
Estrogens | 2 | 2012 | 1536 | 0.490 |
Why?
|
Burnout, Professional | 1 | 2023 | 711 | 0.480 |
Why?
|
Arthralgia | 2 | 2019 | 459 | 0.470 |
Why?
|
Disabled Persons | 1 | 2024 | 1210 | 0.460 |
Why?
|
Telephone | 3 | 2014 | 630 | 0.460 |
Why?
|
Lymph Nodes | 2 | 2016 | 3472 | 0.450 |
Why?
|
Gonadal Steroid Hormones | 2 | 2021 | 707 | 0.430 |
Why?
|
Middle Aged | 65 | 2024 | 223422 | 0.420 |
Why?
|
Adult | 56 | 2024 | 223583 | 0.410 |
Why?
|
Ovarian Neoplasms | 7 | 2023 | 4915 | 0.410 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2024 | 1536 | 0.400 |
Why?
|
Peptide Fragments | 1 | 2024 | 5151 | 0.380 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2021 | 3553 | 0.380 |
Why?
|
Nitriles | 2 | 2014 | 980 | 0.360 |
Why?
|
Aged | 46 | 2024 | 171446 | 0.350 |
Why?
|
Sarcoma | 1 | 2021 | 1804 | 0.350 |
Why?
|
Triazoles | 2 | 2014 | 904 | 0.350 |
Why?
|
Resistance Training | 3 | 2024 | 198 | 0.350 |
Why?
|
Hormone Antagonists | 1 | 2010 | 108 | 0.350 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2012 | 409 | 0.330 |
Why?
|
Energy Metabolism | 3 | 2023 | 2908 | 0.330 |
Why?
|
United States | 23 | 2025 | 73027 | 0.320 |
Why?
|
Practice Guidelines as Topic | 7 | 2021 | 7445 | 0.320 |
Why?
|
Postmenopause | 4 | 2016 | 2518 | 0.320 |
Why?
|
Randomized Controlled Trials as Topic | 11 | 2024 | 10396 | 0.320 |
Why?
|
Health Promotion | 3 | 2016 | 2210 | 0.310 |
Why?
|
Diet, Reducing | 1 | 2012 | 487 | 0.310 |
Why?
|
Leptin | 4 | 2023 | 1599 | 0.310 |
Why?
|
Stress, Psychological | 6 | 2023 | 4530 | 0.310 |
Why?
|
Prognosis | 19 | 2024 | 29979 | 0.300 |
Why?
|
Survival Rate | 7 | 2016 | 12828 | 0.290 |
Why?
|
Complementary Therapies | 2 | 2021 | 487 | 0.280 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 3 | 2010 | 934 | 0.280 |
Why?
|
Women's Health | 4 | 2020 | 2082 | 0.280 |
Why?
|
Epothilones | 2 | 2021 | 42 | 0.280 |
Why?
|
Patient Education as Topic | 3 | 2020 | 2336 | 0.280 |
Why?
|
Body Composition | 5 | 2022 | 2462 | 0.280 |
Why?
|
Treatment Outcome | 25 | 2025 | 65364 | 0.280 |
Why?
|
Taxoids | 3 | 2015 | 665 | 0.270 |
Why?
|
Weight Gain | 4 | 2022 | 2359 | 0.260 |
Why?
|
Physicians | 2 | 2023 | 4598 | 0.260 |
Why?
|
Disease-Free Survival | 11 | 2023 | 6843 | 0.260 |
Why?
|
Patient Care Team | 1 | 2017 | 2521 | 0.260 |
Why?
|
Republic of Korea | 3 | 2024 | 591 | 0.260 |
Why?
|
Muscle Strength | 2 | 2024 | 640 | 0.260 |
Why?
|
Feasibility Studies | 6 | 2022 | 5314 | 0.260 |
Why?
|
Insulin | 5 | 2023 | 6606 | 0.260 |
Why?
|
Colorectal Neoplasms | 5 | 2024 | 6973 | 0.250 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2025 | 300 | 0.240 |
Why?
|
Primary Prevention | 3 | 2019 | 1188 | 0.240 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3929 | 0.240 |
Why?
|
Androgens | 1 | 2012 | 1281 | 0.240 |
Why?
|
Dietary Supplements | 1 | 2017 | 3445 | 0.230 |
Why?
|
Physician's Role | 3 | 2016 | 925 | 0.230 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4055 | 0.230 |
Why?
|
Cause of Death | 3 | 2024 | 3720 | 0.230 |
Why?
|
Maillard Reaction | 1 | 2023 | 8 | 0.230 |
Why?
|
Societies, Medical | 4 | 2017 | 3966 | 0.220 |
Why?
|
Metabolic Diseases | 1 | 2010 | 684 | 0.220 |
Why?
|
Organizational Objectives | 2 | 2016 | 426 | 0.220 |
Why?
|
Young Adult | 14 | 2024 | 60048 | 0.220 |
Why?
|
Pilot Projects | 6 | 2021 | 8740 | 0.220 |
Why?
|
Nurse Practitioners | 2 | 2024 | 271 | 0.220 |
Why?
|
Bone Density | 2 | 2016 | 3573 | 0.210 |
Why?
|
Brain Neoplasms | 6 | 2024 | 9116 | 0.210 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2024 | 211 | 0.210 |
Why?
|
Vincristine | 1 | 2024 | 1040 | 0.200 |
Why?
|
Adaptation, Psychological | 5 | 2020 | 2663 | 0.200 |
Why?
|
Depression | 8 | 2023 | 8231 | 0.190 |
Why?
|
Hypoglycemic Agents | 7 | 2024 | 3108 | 0.190 |
Why?
|
Neoplasms, Second Primary | 1 | 2009 | 1061 | 0.190 |
Why?
|
Male | 26 | 2024 | 364641 | 0.180 |
Why?
|
China | 2 | 2024 | 2395 | 0.180 |
Why?
|
Overweight | 6 | 2022 | 2448 | 0.180 |
Why?
|
Vinblastine | 1 | 2002 | 487 | 0.180 |
Why?
|
Intention | 1 | 2023 | 347 | 0.180 |
Why?
|
Mind-Body Relations, Metaphysical | 1 | 2020 | 35 | 0.180 |
Why?
|
Integrative Medicine | 1 | 2021 | 87 | 0.170 |
Why?
|
Neoplasm Staging | 11 | 2020 | 11221 | 0.170 |
Why?
|
Risk Factors | 16 | 2020 | 74936 | 0.170 |
Why?
|
Lung Neoplasms | 2 | 2022 | 13499 | 0.170 |
Why?
|
Music | 1 | 2023 | 247 | 0.170 |
Why?
|
Pain, Postoperative | 2 | 2020 | 1765 | 0.160 |
Why?
|
Follow-Up Studies | 11 | 2024 | 39345 | 0.160 |
Why?
|
Osteoprotegerin | 1 | 2020 | 179 | 0.160 |
Why?
|
Pandemics | 4 | 2023 | 8748 | 0.160 |
Why?
|
Fractures, Bone | 1 | 2011 | 2062 | 0.160 |
Why?
|
Nausea | 1 | 2022 | 682 | 0.160 |
Why?
|
Pituitary-Adrenal System | 1 | 2022 | 555 | 0.160 |
Why?
|
Self Care | 1 | 2024 | 799 | 0.150 |
Why?
|
Vomiting | 1 | 2022 | 655 | 0.150 |
Why?
|
Fertility | 2 | 2023 | 771 | 0.150 |
Why?
|
Endocrine System | 1 | 2019 | 113 | 0.150 |
Why?
|
Interdisciplinary Communication | 2 | 2015 | 937 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 353 | 0.150 |
Why?
|
Biomedical Research | 4 | 2019 | 3463 | 0.150 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2022 | 703 | 0.150 |
Why?
|
Prevalence | 3 | 2024 | 15867 | 0.140 |
Why?
|
Range of Motion, Articular | 1 | 2024 | 1597 | 0.140 |
Why?
|
Clinical Trials as Topic | 7 | 2020 | 8052 | 0.140 |
Why?
|
Shoulder Joint | 1 | 2024 | 745 | 0.140 |
Why?
|
Mastectomy | 2 | 2024 | 1861 | 0.140 |
Why?
|
Saliva | 1 | 2022 | 853 | 0.140 |
Why?
|
Meditation | 1 | 2020 | 257 | 0.140 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2021 | 605 | 0.140 |
Why?
|
Mucin-1 | 1 | 2021 | 537 | 0.130 |
Why?
|
Vegetables | 1 | 2022 | 1199 | 0.130 |
Why?
|
Referral and Consultation | 2 | 2020 | 3619 | 0.130 |
Why?
|
Decision Making | 3 | 2023 | 3952 | 0.130 |
Why?
|
Disease Management | 3 | 2019 | 2533 | 0.130 |
Why?
|
Isoantibodies | 1 | 2000 | 681 | 0.130 |
Why?
|
Tamoxifen | 2 | 2011 | 966 | 0.130 |
Why?
|
Critical Pathways | 1 | 2020 | 476 | 0.130 |
Why?
|
Problem Solving | 1 | 2018 | 443 | 0.130 |
Why?
|
Premenopause | 2 | 2020 | 1039 | 0.130 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2018 | 590 | 0.130 |
Why?
|
Guidelines as Topic | 3 | 2017 | 1395 | 0.130 |
Why?
|
Aged, 80 and over | 11 | 2023 | 59598 | 0.120 |
Why?
|
Lymphedema | 2 | 2019 | 527 | 0.120 |
Why?
|
Blood Glucose | 3 | 2016 | 6429 | 0.120 |
Why?
|
Body Height | 1 | 2021 | 1565 | 0.120 |
Why?
|
Activities of Daily Living | 1 | 2024 | 2429 | 0.120 |
Why?
|
Survival Analysis | 5 | 2016 | 10098 | 0.120 |
Why?
|
Neoplasm Metastasis | 5 | 2024 | 4904 | 0.120 |
Why?
|
Adolescent | 8 | 2024 | 89155 | 0.120 |
Why?
|
Breast | 2 | 2020 | 1976 | 0.110 |
Why?
|
Tai Ji | 1 | 2017 | 291 | 0.110 |
Why?
|
Vitamin B 12 | 1 | 2017 | 529 | 0.110 |
Why?
|
Hydrocortisone | 1 | 2022 | 1840 | 0.110 |
Why?
|
Recovery of Function | 1 | 2024 | 2981 | 0.110 |
Why?
|
Mastectomy, Segmental | 2 | 2016 | 974 | 0.110 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2016 | 1788 | 0.110 |
Why?
|
Adiponectin | 3 | 2023 | 1117 | 0.110 |
Why?
|
Infection Control | 1 | 2021 | 985 | 0.110 |
Why?
|
Estrogen Replacement Therapy | 1 | 2020 | 1209 | 0.110 |
Why?
|
Health Policy | 2 | 2016 | 2698 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2019 | 1474 | 0.100 |
Why?
|
Cyclophosphamide | 2 | 2015 | 2227 | 0.100 |
Why?
|
Insulin Resistance | 3 | 2023 | 3986 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 560 | 0.100 |
Why?
|
Enzyme Inhibitors | 1 | 2003 | 3726 | 0.100 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1412 | 0.100 |
Why?
|
Health Education | 1 | 2019 | 1059 | 0.100 |
Why?
|
Patient Care | 1 | 2017 | 629 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2021 | 1804 | 0.100 |
Why?
|
Income | 1 | 2020 | 1878 | 0.100 |
Why?
|
Doxorubicin | 2 | 2015 | 2234 | 0.100 |
Why?
|
Nutritional Status | 3 | 2025 | 1628 | 0.090 |
Why?
|
Vaccination | 2 | 2014 | 3437 | 0.090 |
Why?
|
Colonic Neoplasms | 2 | 2013 | 2540 | 0.090 |
Why?
|
Interleukin-6 | 2 | 2018 | 3228 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2021 | 2008 | 0.090 |
Why?
|
Receptors, Progesterone | 3 | 2022 | 1160 | 0.090 |
Why?
|
Research Design | 3 | 2023 | 6211 | 0.090 |
Why?
|
Circadian Rhythm | 1 | 2022 | 2591 | 0.090 |
Why?
|
Erectile Dysfunction | 1 | 2014 | 437 | 0.090 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8535 | 0.090 |
Why?
|
Myocardial Infarction | 1 | 2011 | 11519 | 0.090 |
Why?
|
Attention | 1 | 2021 | 2424 | 0.090 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 4857 | 0.090 |
Why?
|
Longitudinal Studies | 6 | 2024 | 14783 | 0.090 |
Why?
|
Benzothiazoles | 1 | 2011 | 248 | 0.090 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2014 | 364 | 0.090 |
Why?
|
Attitude to Health | 1 | 2019 | 2024 | 0.090 |
Why?
|
Immunization | 1 | 2014 | 1218 | 0.090 |
Why?
|
Preoperative Care | 1 | 2019 | 2256 | 0.080 |
Why?
|
Prospective Studies | 8 | 2022 | 54924 | 0.080 |
Why?
|
Cardiovascular Diseases | 2 | 2019 | 15660 | 0.080 |
Why?
|
Pain | 2 | 2022 | 5100 | 0.080 |
Why?
|
Child | 4 | 2023 | 80906 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3435 | 0.080 |
Why?
|
Lymphatic Metastasis | 2 | 2015 | 2908 | 0.080 |
Why?
|
Self Report | 2 | 2021 | 3773 | 0.080 |
Why?
|
Risk Assessment | 5 | 2019 | 24314 | 0.080 |
Why?
|
Stroke | 1 | 2011 | 9755 | 0.080 |
Why?
|
Connecticut | 2 | 2021 | 365 | 0.080 |
Why?
|
Bariatric Surgery | 1 | 2019 | 1003 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5335 | 0.080 |
Why?
|
Receptor, Insulin | 1 | 2013 | 839 | 0.080 |
Why?
|
Cohort Studies | 7 | 2020 | 41749 | 0.080 |
Why?
|
Reference Values | 1 | 2016 | 4938 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2018 | 1444 | 0.080 |
Why?
|
Alcohol Drinking | 2 | 2012 | 4045 | 0.070 |
Why?
|
Cardiology | 1 | 2019 | 1702 | 0.070 |
Why?
|
Catheterization, Central Venous | 1 | 2013 | 537 | 0.070 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3618 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2945 | 0.070 |
Why?
|
Disability Evaluation | 1 | 2014 | 1835 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6517 | 0.070 |
Why?
|
C-Reactive Protein | 4 | 2023 | 3858 | 0.070 |
Why?
|
Motor Activity | 2 | 2014 | 2711 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1369 | 0.070 |
Why?
|
Early Detection of Cancer | 2 | 2019 | 3237 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3514 | 0.070 |
Why?
|
Molecular Weight | 1 | 2009 | 2173 | 0.070 |
Why?
|
Motivation | 2 | 2018 | 2020 | 0.070 |
Why?
|
Waist-Hip Ratio | 1 | 2008 | 520 | 0.070 |
Why?
|
Ambulatory Care | 1 | 2017 | 2781 | 0.070 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12536 | 0.070 |
Why?
|
Risk Reduction Behavior | 1 | 2013 | 1119 | 0.070 |
Why?
|
Population Surveillance | 1 | 2016 | 2594 | 0.070 |
Why?
|
Cognition | 1 | 2023 | 7072 | 0.060 |
Why?
|
Communicable Diseases | 1 | 2014 | 874 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2020 | 22287 | 0.060 |
Why?
|
Anthropometry | 1 | 2010 | 1346 | 0.060 |
Why?
|
Statistics, Nonparametric | 3 | 2015 | 2863 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2002 | 9252 | 0.060 |
Why?
|
Double-Blind Method | 3 | 2023 | 12464 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5706 | 0.060 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2008 | 524 | 0.060 |
Why?
|
Mental Health | 1 | 2019 | 3275 | 0.060 |
Why?
|
Inflammation | 2 | 2023 | 10871 | 0.060 |
Why?
|
Pain Measurement | 1 | 2014 | 3583 | 0.060 |
Why?
|
Smoking | 2 | 2012 | 9089 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5196 | 0.060 |
Why?
|
Rectal Neoplasms | 1 | 2013 | 1183 | 0.060 |
Why?
|
Time Factors | 3 | 2014 | 40214 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2019 | 10470 | 0.050 |
Why?
|
Research | 1 | 2011 | 1979 | 0.050 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 2016 | 416 | 0.050 |
Why?
|
Comorbidity | 2 | 2020 | 10590 | 0.050 |
Why?
|
Diabetes Mellitus | 2 | 2013 | 5887 | 0.050 |
Why?
|
Qualitative Research | 2 | 2024 | 3140 | 0.050 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 26375 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2000 | 5717 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15944 | 0.050 |
Why?
|
Platinum Compounds | 1 | 2002 | 94 | 0.050 |
Why?
|
Hypesthesia | 1 | 2021 | 106 | 0.050 |
Why?
|
Inpatients | 1 | 2013 | 2570 | 0.050 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2023 | 1942 | 0.050 |
Why?
|
Social Class | 1 | 2010 | 2007 | 0.050 |
Why?
|
Macrophages | 1 | 2016 | 5799 | 0.050 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2024 | 617 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2023 | 81746 | 0.040 |
Why?
|
Holistic Health | 1 | 2020 | 47 | 0.040 |
Why?
|
NAD | 1 | 2024 | 618 | 0.040 |
Why?
|
Neovascularization, Pathologic | 2 | 2024 | 2630 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2014 | 3977 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2017 | 6371 | 0.040 |
Why?
|
Nerve Degeneration | 1 | 2024 | 749 | 0.040 |
Why?
|
Recurrence | 1 | 2012 | 8507 | 0.040 |
Why?
|
Heart Failure | 1 | 2024 | 11883 | 0.040 |
Why?
|
Patient Compliance | 2 | 2021 | 2697 | 0.040 |
Why?
|
Infant | 2 | 2019 | 36534 | 0.040 |
Why?
|
Risk | 1 | 2011 | 9609 | 0.040 |
Why?
|
Length of Stay | 1 | 2013 | 6495 | 0.040 |
Why?
|
Utah | 1 | 2018 | 130 | 0.040 |
Why?
|
Child, Preschool | 2 | 2019 | 42665 | 0.040 |
Why?
|
Physician Assistants | 1 | 2021 | 190 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2002 | 681 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11101 | 0.040 |
Why?
|
Evidence-Based Medicine | 2 | 2021 | 3701 | 0.040 |
Why?
|
Primary Health Care | 1 | 2015 | 4746 | 0.040 |
Why?
|
Pancreatic Neoplasms | 1 | 2016 | 5446 | 0.040 |
Why?
|
Cytokines | 1 | 2013 | 7450 | 0.040 |
Why?
|
Canada | 1 | 2023 | 2129 | 0.040 |
Why?
|
Platelet Transfusion | 1 | 2000 | 301 | 0.040 |
Why?
|
User-Computer Interface | 1 | 2024 | 1407 | 0.040 |
Why?
|
Methylmalonic Acid | 1 | 2017 | 51 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 564 | 0.040 |
Why?
|
Mammography | 1 | 2008 | 2433 | 0.030 |
Why?
|
Placebos | 1 | 2021 | 1667 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2012 | 878 | 0.030 |
Why?
|
Ideal Body Weight | 1 | 2016 | 27 | 0.030 |
Why?
|
Axons | 1 | 2024 | 1677 | 0.030 |
Why?
|
Incidence | 2 | 2012 | 21532 | 0.030 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2016 | 126 | 0.030 |
Why?
|
Research Personnel | 1 | 2021 | 589 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2003 | 1273 | 0.030 |
Why?
|
Odds Ratio | 3 | 2015 | 9666 | 0.030 |
Why?
|
Mentors | 1 | 2021 | 671 | 0.030 |
Why?
|
Behavior Therapy | 1 | 2021 | 886 | 0.030 |
Why?
|
Community Health Centers | 1 | 2019 | 469 | 0.030 |
Why?
|
Fasting | 1 | 2021 | 1609 | 0.030 |
Why?
|
Mice, Obese | 1 | 2016 | 417 | 0.030 |
Why?
|
HLA Antigens | 1 | 2000 | 1334 | 0.030 |
Why?
|
Body Size | 1 | 2017 | 463 | 0.030 |
Why?
|
Community Health Services | 1 | 2019 | 659 | 0.030 |
Why?
|
Exercise Tolerance | 1 | 2019 | 846 | 0.030 |
Why?
|
Switzerland | 1 | 2015 | 323 | 0.030 |
Why?
|
American Heart Association | 1 | 2019 | 1050 | 0.030 |
Why?
|
Administration, Oral | 1 | 2022 | 4030 | 0.030 |
Why?
|
Homocysteine | 1 | 2017 | 637 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2003 | 2197 | 0.030 |
Why?
|
Estradiol | 1 | 2021 | 1951 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2019 | 905 | 0.030 |
Why?
|
Occupational Therapy | 1 | 2014 | 141 | 0.030 |
Why?
|
Thinness | 1 | 2016 | 482 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2000 | 1179 | 0.030 |
Why?
|
Algorithms | 2 | 2024 | 14163 | 0.020 |
Why?
|
Lipids | 1 | 2023 | 3342 | 0.020 |
Why?
|
Exercise Test | 1 | 2019 | 2186 | 0.020 |
Why?
|
Behavior | 1 | 2014 | 541 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2019 | 951 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2013 | 12252 | 0.020 |
Why?
|
North America | 1 | 2015 | 1289 | 0.020 |
Why?
|
Standard of Care | 1 | 2015 | 568 | 0.020 |
Why?
|
Age Factors | 2 | 2020 | 18407 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 3813 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2021 | 2235 | 0.020 |
Why?
|
Gastric Bypass | 1 | 2019 | 824 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2016 | 1758 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 1078 | 0.020 |
Why?
|
Piperazines | 1 | 2021 | 2552 | 0.020 |
Why?
|
Nurses | 1 | 2020 | 2501 | 0.020 |
Why?
|
Methylphenidate | 1 | 2014 | 480 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2013 | 592 | 0.020 |
Why?
|
Testosterone | 1 | 2021 | 2491 | 0.020 |
Why?
|
Catheter-Related Infections | 1 | 2013 | 275 | 0.020 |
Why?
|
Epidemiologic Research Design | 1 | 2013 | 368 | 0.020 |
Why?
|
Economics | 1 | 2010 | 141 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2013 | 794 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 3210 | 0.020 |
Why?
|
Pyridines | 1 | 2021 | 2893 | 0.020 |
Why?
|
Marital Status | 1 | 2010 | 426 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2783 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 2010 | 1625 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2013 | 1363 | 0.020 |
Why?
|
Colectomy | 1 | 2013 | 696 | 0.020 |
Why?
|
Benzhydryl Compounds | 1 | 2014 | 944 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2013 | 2923 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2011 | 2227 | 0.020 |
Why?
|
Postoperative Care | 1 | 2013 | 1480 | 0.020 |
Why?
|
Central Nervous System Stimulants | 1 | 2014 | 1168 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2013 | 1512 | 0.020 |
Why?
|
Anti-Infective Agents | 1 | 2013 | 983 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10757 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3269 | 0.020 |
Why?
|
Palliative Care | 1 | 2020 | 3642 | 0.020 |
Why?
|
Blood-Brain Barrier | 1 | 2011 | 1034 | 0.010 |
Why?
|
Physical Examination | 1 | 2010 | 1263 | 0.010 |
Why?
|
Glucose | 1 | 2016 | 4351 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5366 | 0.010 |
Why?
|
Remission Induction | 1 | 2009 | 2409 | 0.010 |
Why?
|
Counseling | 1 | 2010 | 1554 | 0.010 |
Why?
|
Educational Status | 1 | 2010 | 2515 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2015 | 3488 | 0.010 |
Why?
|
Databases, Factual | 1 | 2017 | 8082 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 16041 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2013 | 4351 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2016 | 14486 | 0.010 |
Why?
|
Mice | 2 | 2018 | 82024 | 0.010 |
Why?
|
Animals | 3 | 2018 | 169222 | 0.010 |
Why?
|
Thrombosis | 1 | 2013 | 2957 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12075 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2009 | 2902 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 22381 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13665 | 0.010 |
Why?
|
Anticoagulants | 1 | 2013 | 4854 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2024 | 36742 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2012 | 3414 | 0.010 |
Why?
|
Massachusetts | 1 | 2008 | 8888 | 0.010 |
Why?
|
Logistic Models | 1 | 2008 | 13289 | 0.010 |
Why?
|
Models, Biological | 1 | 2009 | 9493 | 0.010 |
Why?
|
Signal Transduction | 1 | 2016 | 23642 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2013 | 26420 | 0.010 |
Why?
|
Mass Screening | 1 | 2008 | 5458 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2008 | 15442 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15831 | 0.010 |
Why?
|